Edition:
United States

Fibrocell Science Inc (FCSC.OQ)

FCSC.OQ on NASDAQ Stock Exchange Capital Market

2.00USD
2:09pm EDT
Change (% chg)

$-0.03 (-1.48%)
Prev Close
$2.03
Open
$2.01
Day's High
$2.03
Day's Low
$2.00
Volume
1,945
Avg. Vol
69,413
52-wk High
$18.80
52-wk Low
$1.75

Select another date:

Mon, May 21 2018

BRIEF-Fibrocell Reports On Interim Results And Progress Of Phase 1/2 Clinical Trial Of FCX-007 Gene Therapy For Recessive Dystrophic Epidermolysis Bullosa

* FIBROCELL REPORTS ON INTERIM RESULTS AND PROGRESS OF PHASE 1/2 CLINICAL TRIAL OF FCX-007 GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA

BRIEF-Fibrocell Reports Q1 Loss Per Share $0.11

* FIBROCELL REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-Fibrocell Announces Review Of Strategic Alternatives

* FIBROCELL SCIENCE INC - HAS ENGAGED CANACCORD GENUITY LLC AS ITS STRATEGIC FINANCIAL ADVISOR TO ASSIST WITH THIS REVIEW PROCESS

BRIEF-Fibrocell Reports 2017 Financial Results And Recent Highlights

* FIBROCELL REPORTS 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS Source text for Eikon: Further company coverage:

BRIEF-Fibrocell Announces FDA Allowance Of Investigational New Drug Application For FCX-013

* FIBROCELL ANNOUNCES FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR THE TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA

Select another date: